Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis
暂无分享,去创建一个
M. Cazzola | F. Passamonti | L. Arcaini | E. Rumi | D. Pietra | M. Lazzarino | C. Vercellati | A. Marcello | C. Elena | M. Ammirabile | L. Pagano | A. Flagiello | R. Tedesco | R. Moratti | Mario Cazzola | Luca Arcaini | Francesco Passamonti | M. Lazzarino | Chiara Elena | A. P. Marcello | Remigio Moratti
[1] M. Cazzola,et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.
[2] M. Cazzola,et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] N. Agarwal,et al. Familial Polycythemia Caused by a Novel Mutation in the Beta Globin Gene: Essential Role of P50 in Evaluation of Familial Polycythemia , 2007, International journal of medical sciences.
[4] M. McMullin,et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. , 2007, Blood.
[5] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[6] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[7] Webb Miller,et al. HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update , 2007, Human mutation.
[8] P. Pucci,et al. Hb J-CAPE TOWN [α92(FG4)Arg→Gln (α1), CGG→CAG] in Southern Italy Found in a Patient with Erythrocytosis , 2007 .
[9] Ferdane Kutlar,et al. Diagnostic Approach to Hemoglobinopathies , 2007, Hemoglobin.
[10] M. Cazzola,et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders , 2006, Cancer.
[11] Alain J Marengo-Rowe,et al. Structure-Function Relations of Human Hemoglobins , 2006, Proceedings.
[12] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[13] V. Jooste,et al. Incidence of chronic Philadelphia chromosome negative (Ph−) myeloproliferative disorders in the Côte d'Or area, France, during 1980–99 , 2005, Journal of internal medicine.
[14] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[15] H. Wajcman,et al. Hemoglobins With High Oxygen Affinity Leading to Erythrocytosis. New Variants and New Concepts , 2005, Hemoglobin.
[16] W. Schröter. Kongenitale nichtsphärocytäre hämolytische Anämie bei 2,3-Diphosphoglyceratmutase-Mangel der Erythrocyten im frühen Säuglingsalter , 1965, Klinische Wochenschrift.
[17] D. Stockton,et al. Congenital polycythemias/erythrocytoses. , 2005, Haematologica.
[18] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[19] P. Johansson,et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99 , 2004, Journal of internal medicine.
[20] J. Hoyer,et al. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose‐6‐phosphate dehydrogenase (G‐6‐PD) deficiency , 2004, American journal of hematology.
[21] A. Salzano,et al. Hb Cardarelli [β86(F2)Ala→Pro]: A New Unstable and Hyperaffine Variant in Association with β+‐Thalassemia , 2004 .
[22] A. Salzano,et al. Hb Cardarelli [beta86(F2)Ala-->Pro]: a new unstable and hyperaffine variant in association with beta(+)-thalassemia. , 2004, Hemoglobin.
[23] A. Tosetto,et al. The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis , 2003, Annals of Internal Medicine.
[24] J. Spivak,et al. Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.
[25] David Mole,et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.
[26] G. Gerli,et al. First case of hemoglobin San Diego in Italy , 2002, American journal of hematology.
[27] H. Blacklock,et al. Idiopathic erythrocytosis – a declining entity , 2001, British journal of haematology.
[28] A. Tefferi,et al. A clinical update in polycythemia vera and essential thrombocythemia. , 2000, The American journal of medicine.
[29] H. Kluin-Nelemans,et al. Hb Malmö [β-97(FG-4)His→Gln] leading to polycythemia in a Dutch family , 1996, Annals of Hematology.
[30] H. Kluin-Nelemans,et al. Hb Malmö [beta-97(FG-4)His-->Gln] leading to polycythemia in a Dutch family. , 1996, Annals of hematology.
[31] G. Modiano,et al. Detection of alpha-globin gene disorders by a simple PCR methodology. , 1996, Haematologica.
[32] G. Semenza,et al. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. , 1995, Blood.
[33] V. Joulin,et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. , 1992, Blood.
[34] A. Mosca,et al. Double heterozygosity for hemoglobin Malmö [beta 97 (FG 4) His----Gln] and beta-thalassemia traits. , 1989, Haematologica.
[35] L. Forman,et al. Effect of oxalate and malonate on red cell metabolism. , 1987, Blood.
[36] Y. Beuzard,et al. Hereditary pyruvate kinase abnormalities associated with erythrocytosis , 1981, American journal of hematology.
[37] W. Engel,et al. The molecular mechanism of the inherited phosphofructokinase deficiency associated with hemolysis and myopathy. , 1980, Blood.
[38] J. Marie,et al. Pyruvate kinase hyperactivity genetically determined metabolic consequences and molecular characterization. , 1980, Blood.
[39] Y. Beuzard,et al. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. , 1978, The Journal of clinical investigation.
[40] J. Garvin,et al. Study of a kindred with partial deficiency of red cell 2,3-diphosphoglycerate mutase (2,3-DPGM) and compensated hemolysis. , 1978, Blood.
[41] G. Brittenham,et al. Hemoglobin Hofu or αβ [126 (H4) Val → Glu] Found in Combination with Hemoglobin S , 1978 .
[42] G. Brittenham,et al. Hemoglobin Hofu or alpha 2 beta 2 [126 (H4) Va1 leads to Glu] found in combination with hemoglobin S. , 1978, Hemoglobin.
[43] J. Adamson,et al. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique. , 1976, Annals of Internal Medicine.
[44] G. Stamatoyannopoulos,et al. Hemoglobinopathic erythrocytosis due to a new electrophoretically silent variant, hemoglobin San Diego (beta109 (G11)val--met). , 1974, The Journal of clinical investigation.
[45] S. Boyer,et al. Hemoglobin Malmö β-97 (FG-4) Histidine→Glutamine: A Cause of Polycythemia , 1972 .
[46] H. Lehmann,et al. Two new pathological haemoglobins: Olmsted beta 141 (H19) Leu leads to Arg and Malmö beta 97 (FG4) His leads to Gln. , 1970, The Biochemical journal.
[47] W. Schröter. [Congenital non-spherocytic hemolytic anemia by 2,3-diphosphoglycerate mutase deficiency of the erythrocytes in early infancy]. , 1965, Klinische Wochenschrift.